• Brinsupri, a recently approved drug for bronchiectasis, posted $144.6 million in sales in its full quarter of 2025.
  • The sales figure exceeded initial projections, indicating robust market acceptance.
  • Bronchiectasis is a chronic lung condition with significant unmet medical needs, underscoring the importance of new therapeutic options.

Market Implications

  • The drug's blowout sales performance may enhance Insmed's position in pulmonary therapeutics.
  • Positive early sales can drive further research and potential expansion in related indications.

Source: BioSpace